Autoinhibitory structure of preligand association state implicates a new strategy to attain effective DR5 receptor activation.

导出 OA

翻译打印收藏纠错

第一作者： Gang,Du

第一单位： Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

作者： Gang,Du ^[1] ; Linlin,Zhao ^[1] ; Yumei,Zheng ^[2] ; Anissa,Belfetmi ^[1] ; Tiantian,Cai ^[3] ; Boying,Xu ^[1] ; Karen,Heyninck ^[1] ; Kim,Van Den Heede ^[2] ; Marie-Ange,Buyse ^[4] ; Pietro,Fontana ^[4] ; Michael,Bowman ^[4] ; Lih-Ling,Lin ^[1] ; Hao,Wu ^[3] ; James Jeiwen,Chou ^[5]

作者单位： Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. ^[1] Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. ^[2] Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA. ^[3] Sanofi, Technologiepark 21, Zwijnaarde, Belgium. ^[4] Checkpoint Immunology, Immunology & Inflammation, Sanofi, Cambridge, MA, USA. ^[5] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. wu@crystal.harvard.edu. ^[6] Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA. wu@crystal.harvard.edu. ^[7] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. james_chou@hms.harvard.edu. ^[8]